Document Detail


Sustained use of xylometazoline nasal spray shortens the decongestive response and induces rebound swelling.
MedLine Citation:
PMID:  7540314     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Long-term use of topical vasoconstrictors for the nose may result in rhinitis medicamentosa, drug addiction and tachyphylaxis. Some authors also believe that the severity of rebound swelling is proportional to the period during which the drug has been used, the frequency of its administration, and the amount of drug given. It has previously been reported that four-week use of the recommended dose of oxymetazoline induces rebound swelling, a sign of rhinitis medicamentosa. To study the effect of an increased amount of vasoconstrictor on rebound swelling and the decongestive effect of the drug, nine healthy subjects were given xylometazoline nasal spray in double the recommended dose (1.0 mg/ml; 0.28 ml in each nostril thrice daily) for 30 days. After 30 days on xylometazoline, the decongestive effect was the same 1 h after drug administration as before starting the medication. Similarly, after 30 days on xylometazoline, the decongestive effect was less 5 h after drug administration than it was 6 h after drug administration at the start of medication (p < 0.005). After 10 days no rebound swelling was recorded, but after 30 days rebound swelling occurred in eight out of nine subjects (p < 0.05). When comparing the results of this trial with the corresponding results of the oxymetazoline study, no further increase in rebound swelling was found. We conclude that long-term use of xylometazoline nasal spray shortens the decongestive response in healthy volunteers. Moreover, double the recommended dose of xylometazoline did not further increase the rebound swelling seen when using the recommended dose of oxymetazoline.
Authors:
P Graf; J E Juto
Related Documents :
7770614 - Effects of lorazepam on human contrast sensitivity.
21130164 - Development and characterization of parenteral nanoemulsions containing thalidomide.
19936714 - Are attention lapses related to d-amphetamine liking?
22528504 - Toward global standards for comparator pharmaceutical products: case studies of amoxici...
21303254 - Drug use among prisoners: by any definition, it's a big problem.
559644 - How much heroin maintenance (containment) in britain?
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Rhinology     Volume:  33     ISSN:  0300-0729     ISO Abbreviation:  Rhinology     Publication Date:  1995 Mar 
Date Detail:
Created Date:  1995-07-14     Completed Date:  1995-07-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0347242     Medline TA:  Rhinology     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  14-7     Citation Subset:  IM    
Affiliation:
Department of Otorhinolaryngology, Södersjukhuset, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aerosols
Female
Humans
Imidazoles / administration & dosage,  adverse effects*,  pharmacology
Male
Nasal Decongestants / administration & dosage,  adverse effects*,  pharmacology
Nasal Mucosa / drug effects
Rhinitis / chemically induced*
Time Factors
Turbinates / drug effects
Chemical
Reg. No./Substance:
0/Aerosols; 0/Imidazoles; 0/Nasal Decongestants; 526-36-3/xylometazoline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The airflow resistance profile of healthy nasal cavities.
Next Document:  Septal surgery and tubal function: early and late results.